Meeting
2016 ASCO Annual Meeting
Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose interleukin 2 in metastatic renal cell carcinoma patients (CTEP#7870).
Authors
Roberto Pili
Roswell Park Cancer Institute, Buffalo, NY
Roberto Pili , David I. Quinn , Hans J. Hammers , Paul Monk III, Saby George , Tanya B. Dorff , Thomas Olencki , Li Shen , Dominick M Lamonica , Alan Hutson , Adrienne Groman , Richard Piekarz , Michael Anthony Carducci
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT01038778
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4560)
DOI
10.1200/JCO.2016.34.15_suppl.4560
Abstract #
4560
Poster Bd #
182
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
Phase I study of high-dose interleukin 2, aldesleukin, in combination with the histone deacetylase inhibitor, entinostat, in patients with metastatic renal cell carcinoma: Safety and tolerability results.
First Author: Roberto Pili
Poster
2020 ASCO Virtual Scientific Program
Immunomodulation by HDAC inhibition: Results from a phase I study with entinostat in combination with atezolizumab and bevacizumab in metastatic renal cell carcinoma patients.
First Author: Roberto Pili
Poster
2023 ASCO Annual Meeting
OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti‑PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.
First Author: Paolo Antonio Ascierto
Poster
2019 ASCO Annual Meeting
THOR-707: Using synthetic biology to reprogram the therapeutic activity of interleukin-2 (IL-2).
First Author: Marcos E Milla